Bio-Rad’s ProteOn™ XPR36 protein interaction system and Integral Molecular’s Lipoparticle technology provide high-throughput kinetic analysis of membrane protein interactions.

Date: 
2/15/10

Hercules, CA — February 15, 2010 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the availability of the CFX automation system for walk-away, high-throughput qPCR on its CFX96 and CFX384 real-time PCR detection systems.

In the pharmaceutical and biopharmaceutical markets, performance, time-to-result, and sample throughput are increasingly important. The addition of the CFX automation system to the CFX96 and CFX384 real-time PCR systems offers a high quality, high-throughput, automated PCR solution for these researchers.

"The time needed to run multiple PCR plates is one of the major bottlenecks in generating real-time PCR data," said Richard Kurtz, Marketing Manager, Amplification, Bio Rad Laboratories. "The CFX automation platform eliminates the need for a researcher to be present to load the PCR plate and start each run individually. Now all they need to do is load the stacker, setup the runs, and walk away."

The CFX automation system is equipped with a benchtop plate handler with the capacity to load up to twenty 384-well plates or 7,680 samples at a time on the CFX384 system, facilitating workflow automation, generation of large volumes of data, and rapid analysis of that data.

CFX automation control software manages the configuration and operation of the CFX automation system with one CFX96 or CFX384 real-time PCR detection system, ensuring maximum productivity. Researchers can use the CFX automation control software to define PCR protocols for multiple experiments at once, enabling either the same protocol to be applied across each plate or different protocols for each plate.

Upon run completion, users can analyze data when and where they want by choosing to be sent an email notification with an attached data file. They can also request an automatically generated PDF report in addition to the data file. For more information please visit www.bio-rad.com/amplification.

About the CFX96 and CFX384 Systems
Using the Bio-Rad C1000™ thermal cycler chassis as the base thermal cycler instrument, the CFX96 and CFX384 real-time PCR detection systems incorporate innovative optical technologies and software to deliver sensitive, reliable detection for real-time PCR applications, including absolute quantitation, genetic variation analysis, and gene expression. Both systems read each well individually with high sensitivity and no cross talk to deliver optimal quantitative results. The CFX96 and CFX384 systems provide excellent performance in uniformity, dynamic range of detection and multiplexing capabilities, and they can be operated in several control configurations, including a stand-alone mode with no computer attached. With the CFX384 system, researchers have access to high-throughput real-time PCR in a 384-well format without having to sacrifice convenience and flexibility. For more information please visit www.bio-rad.com/amplification/.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

NOTE TO THE EDITOR:
Information in this release applies specifically to products available in the United States. Product availability and specifications may vary in non U.S. markets.

If you choose to review this item, your readers will receive the quickest response to their inquiries by emailing them to lsg.orders.us@bio-rad.com or by calling 1-800-424-6723.

For more information contact:
Richard Kurtz
Bio-Rad Laboratories, Inc.
800-876-3425x 5638
Richard_Kurtz@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436
kli@chempetitive.com